Suppr超能文献

一种新型人源化抗 Cripto-1 抗体抑制癌细胞生长。

A Novel Artificially Humanized Anti-Cripto-1 Antibody Suppressing Cancer Cell Growth.

机构信息

GSP Enterprise, Inc., 1-4-38 12F Minato-machi, Naniwaku, Osaka 556-0017, Japan.

Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University, Okayama 700-8530, Japan.

出版信息

Int J Mol Sci. 2021 Feb 8;22(4):1709. doi: 10.3390/ijms22041709.

Abstract

Cripto-1 is a member of the EGF-CFC/FRL1/Cryptic family and is involved in embryonic development and carcinogenesis. We designed a novel anti-Cripto-1 artificial antibody and assessed the recognition to the antigen and the potential to suppress the growth of cancer stem cells. First, single chain antibody clones were isolated by bio-panning with the affinity to recombinant Cripto-1 protein from our original phage-display library. Then, the variable regions of heavy chain VH and light chain VL in each clone were fused to constant regions of heavy chain CH and light chain CL regions respectively. These fused genes were expressed in ExpiCHO-S cells to produce artificial humanized antibodies against Cripto-1. After evaluation of the expression levels, one clone was selected and the anti-Cripto-1 antibody was produced and purified. The purified antibody showed affinity to recombinant Cripto-1 at 1.1 pmol and immunoreactivity to cancer tissues and cell lines. The antibody was available to detect the immunoreactivity in tissue microarrays of malignant tumors as well as in Cripto-1 overexpressing cells. Simultaneously, the antibody exhibited the potential to suppress the growth of human colon cancer derived GEO cells overexpressing Cripto-1 with IC at approximately 110 nM. The artificially humanized antibody is proposed to be a good candidate to target cancer cells overexpressing Cripto-1.

摘要

Cripto-1 是 EGF-CFC/FRL1/Cryptic 家族的成员,参与胚胎发育和肿瘤发生。我们设计了一种新型抗 Cripto-1 人工抗体,并评估了其对抗原的识别能力和抑制癌症干细胞生长的潜力。首先,通过用我们原始噬菌体展示文库中的重组 Cripto-1 蛋白进行亲和淘选,分离出单链抗体克隆。然后,将每个克隆的重链 VH 和轻链 VL 的可变区分别融合到重链 CH 和轻链 CL 区的恒定区。这些融合基因在 ExpiCHO-S 细胞中表达,以产生针对 Cripto-1 的人工人源化抗体。在评估表达水平后,选择一个克隆,并生产和纯化抗 Cripto-1 抗体。纯化的抗体以 1.1pmol 的亲和力与重组 Cripto-1 结合,并与癌症组织和细胞系具有免疫反应性。该抗体可用于检测恶性肿瘤组织微阵列以及 Cripto-1 过表达细胞中的免疫反应性。同时,该抗体显示出抑制过表达 Cripto-1 的人结肠癌细胞 GEO 生长的潜力,IC 约为 110nM。该人工人源化抗体有望成为针对过表达 Cripto-1 的癌细胞的良好候选物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6908/7915030/19c5e3cd939a/ijms-22-01709-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验